Abstract
Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Current Alzheimer Research
Title:Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Volume: 14 Issue: 9
Author(s): Stephen M. Meyer, Kristina A. Bertzos, Magdalena Perez, Donald J. Connor*, Kimberly Schafer and Sarah Walter
Affiliation:
- Consultants in Cognitive and Clinical Trials,United States
Keywords: Alzheimer's Disease Assessment Scale (ADAS), Alzheimer’s disease, clinical trials, outcomes, rater, survey.
Abstract: Background: The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog) remains the most widely used test of longitudinal cognitive functioning in Alzheimer’s disease (AD) clinical trials. Unlike most neuropsychological tests, the ADAS-Cog source documentation worksheets are not uniform across clinical trials, and vary by document layout, inclusion of administration and/or scoring instructions, and documentation of subtest scoring (e.g., recording correct versus incorrect scores), among other differences. Many ADAS-Cog test administrators (raters) participate in multiple AD trials and switching between different ADAS-Cog worksheets may increase the likelihood of administration and/or scoring mistakes that lessen the reliability of the instrument. An anonymous online survey sought raters’ experiences with ADAS-Cog worksheets and their opinions on the design and content of the worksheets.
Results: Results of the survey indicated preference for structure and standardization of the ADASCog worksheets, which has been considered in the development of a standard ADAS-Cog source document by the Alzheimer’s Disease Cooperative Study (ADCS) Working Group.Export Options
About this article
Cite this article as:
Meyer M. Stephen , Bertzos A. Kristina , Perez Magdalena , Connor J. Donald*, Schafer Kimberly and Walter Sarah , Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions, Current Alzheimer Research 2017; 14 (9) . https://dx.doi.org/10.2174/1567205014666170417122744
DOI https://dx.doi.org/10.2174/1567205014666170417122744 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Migraine and Obesity: Is There a Relationship? A Systematic Review and Meta-Analysis of Observational Studies
CNS & Neurological Disorders - Drug Targets Commentary: Research Highlights: IKKβ Mediates Aβ-Triggered Microglial Inflammation and Neuronal Death During Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Aging is Not a Disorder
Current Aging Science Glial Cells – The Key Elements of Alzheimer´s Disease
Current Alzheimer Research Intermittent Transient Motor Aphasia Associated with Acute Lithium Toxicity: A Case Report and Brief Review
Current Drug Safety Meet Our Editorial Board Member
Current Neuropharmacology <i>In Vivo/Ex Vivo</i> EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease
Current Alzheimer Research Role of Estradiol and Progesterone in HIV Susceptibility and Disease Progression
Mini-Reviews in Medicinal Chemistry Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses
Current Pharmaceutical Biotechnology Effect of Barley Grain on Memory and Brain’s Oxidative Stress Factors in Male Rats
The Natural Products Journal Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Natural Non-Trasgenic Animal Models for Research in Alzheimers Disease
Current Alzheimer Research Pharmacogenetics and Pharmagenomics, Trends in Normal and Pathological Aging Studies: Focus on p53
Current Pharmaceutical Design Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Letters in Drug Design & Discovery